scientists may also be focusing on ultra-very long-acting GLP-1 analogs that may need dosing just once a month or simply considerably less frequently. These prolonged-release versions could allow it to be even much easier to follow getting GLP-1s.  Semaglutide imitates the steps of GLP one by stimulating insulin output within the pancreatic beta